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Abstract 
The SARS-CoV-2 pandemic is without doubt one of the greatest challenges modern medicine has ever 
faced. To date there is still no cure and effective treatments are desperately required to combat both the 
viral infection and the wide variety of consequent pathologies displayed in COVID-19 patients. One of 
the most severe pathologies seen in patients with COVID-19 is pulmonary fibrosis resulting from the 
cytokine storm generated, which activates fibroblasts leading to the progressive accumulation of 
collagen fibres in the lungs. Pulmonary fibrosis compromises lung function and can ultimately lead to 
respiratory failure. Type II pneumocytes (ATII) are particularly susceptible to Sars-CoV-2 infection. 
ATII cells are responsible for the production of surfactant Protein C (SPC) and other surfactant 
components fundamental to lung integrity. In this study ATII cells were isolated from non-covid 
patient´s lungs and characterized by a specific enzymatic test. The expression of SPC in ATII cells was 
tested under different conditions mimicking those of COVID-19 disease.  
Many plants possess a variety of secondary metabolites with antibiotic, antifungal and antiviral 
properties and are the basis for many traditional and modern medicines. In this study, we analysed the 
effect of different plant extracts from Marchantia and Arabidopsis mutants on SPC expression in the 
presence of Transforming Growth Factor β (TGF- β) as a representative cytokine of the cytokine storm.   
Preliminary results indicated that some of the tested plant extracts could provide some protection against 




Coronavirus disease 2019 (COVID-19) is an ongoing pandemic which first appeared in December 2019 
in Wuhan city of the Hubei province in China. The disease rapidly spread globally and to date has 
infected over 176 million people and caused 3.81 million deaths (1). It is caused by a novel 
Betacoronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2). 
SARS-CoV-2 primarily affects the respiratory system, similar to the previous coronavirus outbreaks of 
severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (3). 
Infection can be asymptomatic or present only mild symptoms, commonly similar to those of seasonal 
flu, however in some cases can cause systemic hyperinflammation, pulmonary fibrosis, lung collapse, 
multi-organ dysfunction, and death (4). Various vaccines against the virus have been developed at an 
unprecedented rate however there is still an urgent need for focusing research and funding into the 
development of novel treatments for SARS-CoV-2 infected patients to reduce mortality and to treat the 
resulting pathologies caused.  
 
Viral entry 
The virus enters the respiratory tract where the viral surface spike (S) glycoprotein binds to angiotensin-
converting enzyme 2 (ACE2) receptors of epithelial cells, particularly Type II Alveolar Epithelial Cells 
(ATII) (5). SARS-CoV-2 uses the same receptor as its main point of entry as SARS-Co-V but has a 
higher binding affinity, thought to increase transmission ability (5). Proteolytic cleavage of the S 
protein, by both Transmembrane Protease Serine 2 (TMPRSS2) and Furin proteases, is required to 
enable viral cell entry (5). Furin is ubiquitously expressed whereas TMPRSS2 and ACE2 are co-
expressed within nasal epithelial cells and in ATII cells within the lungs and bronchial branches, which 
explains some of the tissue tropism of SARS-CoV-2 (5).  
 
Infection and cytokine storm 
SARS-CoV-2 generally infects the upper respiratory track and symptoms typically include fever, 
headache, and cough. As the virus starts replicating and migrating down the airways, it is detected by 
pathogen recognition receptors of immune cells triggering the innate immune system and the release of 
cytokines and chemokines (6). These are responsible for initiating a complex system of signalling 
thereby inducing inflammation, the recruitment of more immune cells and activation, proliferation, and 
cell differentiation of innate and adaptive responses (6). The major cytokines produced are Interleukin 
(IL)-1α/β, IL-18 and IL-6, tumour necrosis factor (TNF)-α, Interferon (IFN)-α/β and Transforming 
growth factor (TGF)-β; while the major chemokines produced are Monocyte Chemoattractant Protein 
(MCP)-1, MCP-3, Macro-phage Inflammatory Protein (MIP-1-α), CCL-5 (Chemokine (C-C motif) 
ligand 5) and IFN-γ-inducible protein-10 (IP-10) (6). Severe cases have been attributed to a maladaptive 
or imbalanced immune response with chronic, exacerbated cytokine release and apoptosis of epithelial 
and endothelial cells, followed by vascular leakage and an abnormal T cell and macrophage response 
(6). The virus also has various mechanisms for avoiding or delaying detection thereby increasing viral 
load and facilitating progression to the lower respiratory airways and infecting the alveolar space where 
gas exchange takes place causing pneumonia which can lead to inflammatory-induced acute lung injury 
and acute respiratory distress syndrome (ARDS) (5).  
In most moribund patients, a cytokine storm can be observed, characterized by high serum 
concentrations of IL 1, 6, 8 and 10, TNF-α, granulocyte colony-stimulating factor, MCP-1, MIP-1-α, 
and IP-10 and can eventually lead to multiple organ failure (7, 8). The hyperactive inflammatory state 
caused by the cytokine storm in severe cases of SARS-CoV-2 infection, and the elevated levels of the 
growth factors and cytokines TGF-β, Il-6, and TNF-α, are most likely the main causes of pulmonary 
fibrosis (4). 
 
Type II Alveolar Epithelial Cells (ATII) 
The pulmonary alveolar epithelium is composed of two types of differentiated epithelial cells:  
Alveolar type 1 (ATI) cells which account for 85-90% of all alveolar cells and are responsible for 
mediating gas exchange and alveolar type 2 (ATII) cells which account for 10-15% and are responsible 
for the production and secretion of surfactant components which reduce the superficial tension of fluid 
inside alveoli (5). Surfactant is a thin aqueous film coating the surface of the alveolar and its tension 
reducing function comes from interaction between phospholipids and two hydrophobic proteins, 
surfactant protein B (SPB) and surfactant protein C (SPC)(9). The reduction in superficial tension 
prevents alveolar collapse and is fundamental to lung integrity (5). SPC also plays a role in maintaining 
alveolar epithelial homeostasis abnormal expression of SPC is seen in the development of lung disease 
and microbial pulmonary infection(9). ATII cells also play fundamental roles in immune defence and 
regeneration during and following lung injury (5). They are the progenitors of ATI cells and therefore 
have the capacity for both self-renewal and differentiation to ATI cells (5). As ATII cells co-express 
TMPRSS2 and ACE2 enabling viral entry, these cells are particularly susceptible to Sars-CoV-2 
infection (10). ATII cells are being infected and dying therefore secretion of surfactant components is 
decreased, and the fluid tension rises creating a stickiness (10). The increased stickiness leads to a 
reduction in gas exchange, and further contributes to the uncontrolled inflammation brought about by 
the innate immune response leading to collapsing of alveoli and ARDS (10).  
 
SARS-CoV-2 and pulmonary fibrosis 
Pulmonary fibrosis is commonplace following severe and/or persistent lung damage from a variety of 
causes such as respiratory infections, connective tissue disorders, chronic granulomatous diseases or 
medications (3). Clinical, radiographic and autopsy reports show this was also the case following SARS 
and MERS infection (3). Some patients who had previously been infected with SARS or MERS were 
found to have residual pulmonary fibrosis two years after hospital discharge (11). Following recovery 
from COVID-19, many patients who had suffered from ARDS or severe pneumonia were found to have 
pulmonary fibrosis (12). One study, assessing 284 hospitalized patients who achieved a clinical cure, 
found that pulmonary fibrosis occurred in 100% of patients suffering from severe or critical COVID-
19 and in 84.15% of total hospitalized patients (11). The results also indicated that patients suffering 
from moderate COVID-19 predominantly develop mild-to-moderate pulmonary fibrosis whereas 
patients suffering with critical COVID-19 mainly develop severe fibrosis (11). Pathological 
manifestations of COVID-19 strongly resemble those of SARS and MERS however, whether or not it 
can cause irreversible pulmonary fibrosis needs more investigation (11). As in previous coronavirus 
outbreaks, SARS-CoV-2 can also induce an excessive, aberrant and non-effective immune response 
leading to severe inflammation initiating a profibrotic response (12). For those who survive intensive 
care, excessive and prolonged cytokine overexpression can cause long-term lung damage, including 
fibrosis that could promote lung function decline, a significant reduction in quality of life and, in severe 
cases, is associated with increased mortality (7).  
Fibrosis is a pathophysiological condition characterized by excessive production and deposition of 
extracellular matrix (ECM) proteins causing scarring of the tissue (13). The ECM provides a scaffold 
for residing cells within a tissue or organ as well as mediating certain cellular functions such as 
adhesion, migration, proliferation, and differentiation (5). ECM composition varies between tissues but 
is primarily composed of collagens while also contains elastic fibres, fibronectin, laminins, 
proteoglycans and glycosaminoglycans (5). Fibrosis is due to a maladaptive or disordered wound 
healing as a result of injury or disease, this is initially a protective mechanism that attempts to preserve 
structure and function and can be beneficial for healing and tissue regeneration however, when damage 
is severe or persistent there is an excessive or continuous accumulation of ECM components, resulting 
in fibrosis (13). Pulmonary fibrosis remodels tissue architecture causing a thickening and stiffening of 
the tissue around and between the alveoli thereby impairing lung function and can ultimately result in 
organ failure (11). The mechanisms responsible for the pathogenesis of fibrosis are complex and involve 
interplay between pro-fibrotic cells, growth factors and pro-inflammatory cytokines (14). A key step 
leading to fibrosis is the activation of fibroblasts which induces them to proliferate and differentiate 
into myofibroblasts which in turn secrete significant amounts of ECM proteins and adopt a contractile 
phenotype similar to that of smooth muscle tissue (15). Transforming growth factor beta (TGF-β) is the 
best characterized fibrogenic growth factor and considered the most important cytokine implicated in 
the recruitment and activation of fibroblasts in response to chronic injury. TGF-β signalling is initiated 
when TGF-β binds to form a complex with the transmembrane serine/threonine kinase receptors TGF-
βRI and TGF-βRII, leading to the activation of a cascade of intracellular mediators (16). The canonical 
pathway induced by TGF-β involves Smad proteins whereby the active receptor complex 
phosphorylates Smad2 or Smad3 propagating the signal (16). Smad2/3 can then form a complex with 
Smad4 which translocate to the nucleus to initiate a transcriptional response resulting in ECM synthesis 
(16). 
 
Vaccines and treatments 
No specific anti-viral treatment exists against SARS-CoV-2 (7). Clinical treatment is mainly limited to 
symptomatic treatment and organ support in intensive care from patients with COVID-19 (7). Since the 
beginning of the outbreak, governments and global public health bodies have mainly focused on 
preventing the viruses spread and the development of vaccines, but as infection rates have remained 
very high in some countries, more effective treatments are desperately needed to combat the virus and 
the large array of symptoms exhibited, thereby reducing mortality and long-term health effects of 
COVID-19. The current vaccination efforts are providing promise for a considerable reduction in cases, 
however, there remains a high possibility that the virus won´t ever be eradicated and the emergence of 
new strains risk rendering current vaccines ineffective therefore further highlighting the need for novel 
therapeutics. An anti-fibrotic treatment administered to patients with an ongoing SARS-CoV-2 
infection could prevent deterioration of the clinical situation, in some cases preventing mortality, and 
also prevent residual pulmonary fibrosis following recovery thereby preventing long-term lung function 
impairment (4). Some potential therapeutic strategies could be based on the protection of ATII cell 
homeostasis to prevent cytokine storm-produced fibrosis. 
 
Telomeres  
Cell homeostasis requires the presence of a certain length of telomeres in cells to enable the healthy 
reproduction and repopulation of cells (17). Telomeres are nucleoprotein complexes located at the ends 
of chromosomes comprising of a region of repetitive nucleotide sequence and are essential for 
chromosome protection and genomic integrity (18). In vertebrates, telomeres are comprised of tandem 
repeats of the DNA sequence TTAGGG bound to the six-subunit protein complex known as shelterin 
which enables the cell to distinguish chromosome ends from DNA damage (18). One of the molecular 
pathways underlying aging is the progressive shortening of telomeres leading to a reduced proliferation 
potential of somatic cells (17). This can in-turn cause an increased pressure on proliferating cells, such 
as stem cells and immune cells, to divide more, in order to maintain cell populations within tissues (17). 
Cellular stress due to viral infection or other causes can also necessitate repetitive cell division 
accelerating the aging process and telomere shortening (17). Telomeres become progressively shorter 
with subsequent cell divisions due to the end replication problem where-by the ends of linear DNA of 
the lagging strand, previously occupied by the RNA primer, cannot be replicated completely during 
DNA synthesis (18). Telomeres progressively shorten with increasing age and, when they become 
critically short, can lead to genomic instability, cellular senescence or apoptosis, and loss of the 
regenerative capacity of tissues (18). Lung function is progressively impaired with age leading to an 
increased risk of developing pulmonary disease, lung cancer or idiopathic pulmonary fibrosis (18).  
Telomerase is a reverse transcriptase able to elongate telomeres thereby compensating telomere 
shortening with age (18). It is active in most proliferating cells though its expression is silenced in the 
majority of somatic cell types after birth (18). In the lungs, telomeres of patients with idiopathic 
pulmonary fibrosis are reported to be shorter than those of healthy individuals (18). Inducing telomere 
dysfunction in ATII cells in mice was sufficient to induce pulmonary fibrosis (18). Telomerase-deficient 
and wild-type mice with short telomeres in their lung cells, were treated with bleomycin. Bleomycin is 
primarily used is as an antitumor antibiotic for various carcinomas and lymphomas and pulmonary 
fibrosis is a well-known side effect so it is widely used in experimental models for lung fibrosis (19). 
This treatment induced fibrosis in telomerase-deficient mice, but not in wild-type mice (18). 
Furthermore, treating these mice with telomerase gene therapy, in order to activate telomerase in the 
lung cells, thereby elongating telomeres, was able to prevent the progression of fibrosis (18). Moreover, 
aging also leads to a decrease in proliferation of ATII cells, a phenomenon that is observed earlier in 
telomerase-deficient mice, implying that cells with short or dysfunctional telomeres have a reduced 
capacity for regeneration of tissue (18). It has been found that patients with shorter telomeres are at a 
higher risk of developing severe COVID-19 pathologies (17). It has been hypothesized that the need 
for rapid cellular regeneration caused by SARS-CoV-2 infection, and the reduced capacity for patients 
with short telomeres to fulfil this demand, could be exhausting the regeneration potential of the lungs 
therefore contributing to fibrosis (17). Thus, telomere length and maintenance could serve as a 
prognosis for which patients are more likely to suffer from pulmonary fibrosis and a reduced ATII 
regeneration capacity, as a result of COVID-19. It is unknown though if shortened telomeres are a cause 
or an effect of severe COVID-19 pathology.  
 
Plant extracts 
Plants have been known to display an array of medicinal properties and have been used in traditional 
medicines for thousands of years. Many modern medicines are derived from the numerous chemical 
compounds medicinal plants produce. There are two main categories of phytochemicals produced by 
plants: Primary and secondary metabolites. Primary metabolites are directly involved in growth, 
development and reproduction and therefore similar across species (20). Secondary metabolites are not 
essential for basic life functions and are generally compounds that confer a selective advantage to the 
organism such as protection against biotic or abiotic stresses (21). Some possess antibiotic, antifungal 
and antiviral properties enabling them to protect plants from pathogens (22). Secondary metabolites are 
an abundant source of novel compounds with potential pharmaceutical applications and their biological 
properties as well as strategies for their targeted expression and purification are very active fields of 
research (23). 
Many plants are also able to live for hundreds of years and show distinct telomere maintenance features 
compared to humans such as indefinitely proliferating meristems, reversible regulation of telomerase 
in somatic cells and an absence of developmental telomere shortening (24).  
Two extremely well established and popular biological plant models are Arabidopsis and Marchantia. 
Arabidopsis is a popular model organism in plant biology and the first plant to have its genome 
sequenced (21). More papers are published on Arabidopsis each year than on each of Saccharomyces, 
Caenorhabditis, Zebrafish, Chicken, or Drosophila and it has largely contributed to our understanding 
of plant development, signalling, hormone biology, pathogen defence, disease resistance, and abiotic 
stress response (25). A large variety of mutant lines of Arabidopsis exist, facilitating genetic and 
physiological analysis and over expression of various secondary metabolites (21). Additional 
advantages to research include its relatively short generation time, small size, diploid genetics and its 
high number of offspring (21). Marchantia is a dioecious liverwort found in most temperate climates 
and known for its ample range of biologically active compounds (26). It has been mentioned in ancient 
Greek texts as a plant used to prevent infection and inflammation of open wounds. Its physiological and 
morphological changes in response to environmental changes have been studied intensely for almost 
200 years (26). Like Arabidopsis, Marchantia is another popular model organism in plant biology 
pertaining the advantages of having had its relatively small, haploid genome sequenced as well as 
having a short life cycle, ease of propagation and crossing and a high frequency of transformation (26). 
Both plants are also of high interest for their potential to produce phytopharmaceutical and nutraceutical 
substances or pharmaceutical proteins (21, 26). 
Other studies have found plant extracts that can ameliorate bleomycin-induced pulmonary fibrosis and 
work in synergy with bleomycin to enhance its anti-cancer activity(27). We hypothesise that by 
protecting ATII cells, this would prevent or reduce the cytokine storm and therefore fibroblasts would 
not be activated, so resulting fibrosis would be reduced. This study will be preparing the conditions 
required for screening various Arabidopsis and Marchantia plant extracts for possible natural protective 
properties in ATII cells, in an environment that recreates the cytokine storm caused by SARS-CoV-2. 
Moreover, we will take preliminary steps to enable telomere measurement in human ATII cells under 





With the overall objective of finding potential plant extract candidates for the prevention or reduction 
of fibrosis in SARS-CoV-2 infection, the objectives of this research are the following: 
 
1: To Extract and purify ATII cells from clinical lung samples and confirm their purity enzymatically.  
 
2: To establish cell viability over a 24-hour period to enable treatment in ATII cells and establish the 
number of cells required to yield sufficient quantities of RNA to allow for retro-transcription and 
detection of surfactant protein C (SPC). 
 
3: To Analyse the effect of TGF-β in ATII cells on SPC gene expression.  
 
4: Establish optimal culture conditions that allow measurement of telomere length via HTQ-FISH 
techniques in ATII cells.  
 
5: Determine the effect of total metabolites of 4 plant extracts from Marchantia and total 4 plant extracts 
from Arabidopsis on SPC expression in ATII cells. 
 
6: To establish the optimal conditions for SARS-CoV-2 infection of ATII cells. 
 
7: To Isolate and culture primary human fibroblasts from clinical lung samples obtained from biopsies 




This project was approved by the bioethics committee of the Hospital de Valdecilla and by the biosafety 
and bioethics committees of the Institute of Biomedicine and Biotechnology of Cantabria. All patients 
have signed their informed consent to take part in this study. Lung sections are used from patients with 
cancer, who undergo lung surgery to remove the tumour. The lung section is the one furthest away from 
the tumour.  
 
Isolation of human ATII cells from clinical lung samples 
Preparation of solutions: 
Physiological saline 0.9% NaCl 0.15M 
Trypsin (T8003-1G) 2.5 mg per 1 ml Hank′s Balanced Salt Solution (HBSS) 
DNase 1(10104159001): 250 µg per 1 ml HBSS 
DNase 2 solution: 100 µg per 1 ml HBSS 
Cell culture medium: Dulbecco's Modified Eagle Medium supplied by Sigma-Aldrich RPMI-1640, 
supplemented with 10% Foetal Bovine Serum (FBS), 1% penicillin-streptomycin and 1% antifungal 
agent Amphotericin B all supplied by Gibco. 
NaCl 0.2% 
NaCl 1.6% 
All solutions were either autoclaved or filtered through a 0.2 µm filter from Minisart.  
In a safety cabinet, samples extracted from patient lungs were washed with physiological saline using 
a syringe and needle until tissue acquired a grey colour and contained less than 1 x 104 monocytes/ml. 
Tissue was infused with 10-15 ml of trypsin using a syringe and needle until the tissue was inflated. 
Samples were incubated at 37oC for 15 minutes. This process was repeated 3 times replacing the trypsin 
each time. Trypsin was eliminated and samples were cut until blended in the presence of 10ml FBS. 
Samples were transferred to a 50ml falcon and 7ml DNase 1 was added. Solutions were shaken 
vigorously for 5 minutes then filtered a 400-500 µm gauze followed by a 40 µm one. The filtrates were 
centrifuged at 520 xg for 20 minutes at 12ºC the cell pellets resuspended in 30 ml of DNase II solution. 
The average number of nucleated cells was determined using a hemacytometer and 500 μl sample was 
taken to perform a cytocentrifuge. Solutions were then incubated on a 150mm tissue culture dish for 2 
hours at 37ºC to eliminate macrophages and adhesive cells. Cell suspension was centrifuged at 520 xg 
for 20 minutes at 12ºC and cell pellets resuspended in 10ml DMEM. The average cell number was 
determined using a haemocytometer and a second sample of 500 μl was taken to perform a 
cytocentrifuge. Cells were then either resuspended in cell culture medium and plated or frozen in cell 
culture medium containing 10% DMSO. To proceed with experimental work using frozen ATII cells, 
cells were defrosted by warming the vial of frozen cells in a water bath at 37ºC for 1 minute, then adding 
1 ml of physiological saline drop by drop while swirling continually. Cells were centrifuged for 10 
minutes at 500 xg and resuspended in cell culture medium. 
 
Alkaline phosphatase histochemical staining of ATII cells 
Purity of ATII cell extractions were measured enzymatically using the Leukocyte Alkaline Phosphatase 
Kit based on naphthol AS-BI and fast red violet LB by Sigma. Cell samples taken during ATII 
extractions were cytocentrifuged onto a microscope slide.  
Diazonium salt solution was prepared by adding 1 ml sodium nitrate solution to 1 ml of FRV-Alkaline 
solution and gently inverted and left to stand for 2 minutes. The solution was added to 45 ml of deionized 
water at room temperature. 1 ml of Naphthol AS-BI Alkaline Solution was added, the solution was 
mixed and added to a Coplin jar.  Slides were fixed by immersing them in Citrate-Acetone-
Formaldehyde Fixative at room temperature for 30 seconds then rinsed gently in deionized water for 45 
seconds. Slides were subsequently added to the alkaline-dye mixture described above and incubated at 
room temperature for 30 minutes while protecting immersed slides from direct light. Slides were 
removed from the Coplin jar and rinsed for 2 minutes in deionized water. They were counterstained for 
2 minutes with Hematoxylin Solution, rinsed under tap water and allowed to air dry. Slides were 
mounted using DPX Mountant from Sigma and samples were digitalized with the AxioScan.Z1 slide 
scanner (Zeiss). Slides were scanned with a x10/NA 0.55 Plan-APO objective (0.442 mm/px) and a 
HV-F201 colour camera with a 1600x1200 pixels sensor and a high-resolution mosaic was exported as 
jpg. White balance, camera exposure time and image brightness were adjusted to maximize colour 
fidelity and contrast. Images were analysed by selecting 4 zoomed sections of each image and 
quantifying the total number of nucleated cells versus the number of pink-purple alkaline phosphatase 
positive ATII cells, and the percentage of ATII cells was calculated by taking the mean of 4 
measurements per sample.  
 
ATII cell viability over a 24-hour period 
Cells were defrosted and the initial cell number of alive and dead cells were established using a 
haemocytometer and by staining dead cells with trypan blue from Gibco. Cells were seeded 100,000 
alive cells per well in 400 μl of cell culture medium on a 24 well plate. After 12 hours of incubation at 
37ºC, both alive and dead cells were counted by taking a sample of the supernatant. At 24 hours, the 
supernatant was collected, attached cells were detached by incubating with 1 ml trypsin-EDTA solution 
from Sigma for 3 minutes and added to the supernatant. Cells were centrifuged at 500 xg for 10 minutes 
and resuspended in the initial volume of 400 μl of cell culture medium. The number of dead and alive 
cells were counted again using a haemocytometer.  
 
Seeding and treating ATII cells 
Cells were counted using a haemocytometer, resuspended in cell culture medium to the required 
concentration, seeded into cell culture dishes and incubated for 2 hours at 37ºC. All treatments and/or 
infections were performed 2 hours after seeding cells and incubated for a further 24 hours at 37ºC before 
being prepared for RNA isolation, or fixation to allow telomere measurement via HTQ-FISH.  
 
Preparation for RNA isolation 
To isolate RNA from ATII cells directly after they had been defrosted, the cells were centrifuged at 500 
xg for 10 minutes, their supernatants were discarded, and the cell pellets were resuspended in 800 μl 
NZYol (MB18501) from Nzytech. RNA was immediately extracted according to the RNA extraction 
protocol outlined below. 
To isolate RNA from ATII cells on plates not prepared for telomere measurement via HTQ-FISH, plates 
were centrifuged as above, supernatants were discarded, and cells were lysed by adding NZYol directly 
to the plates. 800 μl NZYol was used per sample.  
To isolate RNA from ATII cells seeded in 96 well plates allowing for measurement of telomeres via 
HTQ-FISH, the supernatant was harvested in microcentrifuge tubes, centrifuged as above and the cell 
pellets were resuspended in 800 μl NZYol. 
 
RNA isolation 
Following resuspension in NZYol, the cell lysate was pipetted several times to homogenize, and 
samples were incubated for 5 minutes at room temperature. 0.18 ml of chloroform was added to each 
sample, tubes were capped and shaken vigorously for 15 seconds then incubated for 3 minutes at room 
temperature. Samples were centrifuged at 12,000 xg for 15 minutes at 4ºC and the upper aqueous phase 
was transferred to a new tube. RNA was precipitated by mixing 0.4 ml of cold isopropyl alcohol and 
incubated for 10 minutes at -20ºC. Samples were then centrifuged at 12,000 xg for 10 minutes at 4ºC 
and the supernatant was discarded with a micropipette. To wash the RNA, the pellet was resuspended 
in 0.8 ml of 75% ethanol. Samples were centrifuged at 12,000 xg for 5 minutes at 4ºC and the 
supernatant was again discarded. Samples were left to air dry for 15 minutes and the pellet was 
resuspended in 20 μl DEPC-treated water. The RNA concentration of samples was determined using a 
NanoDrop Spectrophotometer from NanoDrop Technologies and samples were stored at -80ºC. 
 
Complimentary DNA (cDNA) Reverse transcription 
Single-stranded cDNA was synthesized using the high-capacity cDNA reverse transcription kit from 
Applied Biosystems. 2 μg of RNA in a volume of 10 μl DEPC-treated water was loaded into a PCR 
tube. A 2X master mix containing 2 μl RT buffer, 0.8 μl dNTP mix, 2 μl RT random primers, 4.2 μl 
nuclease-free water and 1 μl MultiScribe reverse transcriptase per reaction was mixed on ice. 10 μl of 
master mix was added to each 10 μl RNA sample, mixed gently, sealed, and briefly centrifuged to spin 
down contents and eliminate air bubbles. A negative control containing 10 μl of master mix and 10 μl 
of DEPC-treated water was also prepared.  Reactions were loaded to the thermal cycler. The thermal 
cycler was programmed according to the Table 1 and the reaction volume was set to 20 μl.  
Table 1: Program for thermal cycler for cDNA Reverse transcription. 
Temperature (ºC) Step 1 Step 2 Step 3 Step 4 
25 37 85 4 
Time (minutes) 10 120 5 ∞ 
 
SYBR Green Quantitative PCR (qPCR) 
Table 2: Primers and probes used in qPCR. 
Target gene/Probe Forward(F)/Reverse(R) Oligonucleotide sequence 5´to 3´ 
Human S14 (endogenous) F GGGGTGACATCCTCAATCC 
R TATCACCGCCCTACACATCA 
Human SPC F TGGTTACCACTGCCACCTTC 
R CTGGCCCAGCTTAGACGTAG 
 
A master mix for each target gene containing 5 μl SYBR green, 0.3 μl forward primer, 0.3 μl reverse 
primer and 3.4 μl Milli-Q water per reaction was mixed. The sequences of primers used can be seen in 
Table 2. 9 μl of master mix was pipetted into each well of a 0.2 ml PCR reaction plate from Applied 
biosystems. 1 μl of cDNA was loaded to each well. cDNA samples were then amplified by qPCR in 
triplicate reactions for each primer pair assayed on a 7500 Real-Time PCR Instrument (Applied 
Biosystems) using SYBR Premix Ex Taq (Takara Bio) and the following qPCR conditions: 95°C for 2 
min; 40 cycles of 95°C for 15 s, 60°C for 15 s and 72°C for 60 s. Results were normalized using S14 
rRNA gene as the endogenous control. Two negative controls containing 9 μl master mix and either 1 
μl water or 1 μl of negative control from retro transcription were also performed for each target gene. 
Thresholds for gene expression were adjusted on the StepOne software and data was exported and 
analysed in Microsoft Excel. We applied the delta-delta Ct method (2-ΔΔct): ΔΔCt= ΔCt (SPC) – ΔCt 
(S14). 
 
Conditions that allow measurement of telomere length via HTQ-FISH 
techniques in ATII cells 
High-throughput telomere length quantification by FISH allows the quantification of telomere length 
through fluorescence, as well as showing the percentage of short telomeres in human cells, enabling the 
uncovery of associations between telomere length and human disease (28). The technique is aggressive 
and requires treatment at 80ºC so many cells can become detached in the process. Measuring of 
telomeres was carried out by Maria Blasco´s laboratory in CNIO, Madrid who are collaborating in this 
project, so plates also needed be sealed with adhesive plate seals from Thermo Scientific and to 
withstand shipping. Black, clear bottomed microplates from Greiner bio-one were used and depending 
on the type of cells being measured, plate coatings may be required. Cells need to be numerous enough, 
but not too numerous to allow measurement and so the number of cells required varies depending on 
the size of cells, how well they attach to the plate and how many are lost during fixing and measurement 
processes. As the collaborating laboratory had never measured telomeres of ATII cells before, it was 
necessary to find the conditions needed for the technique.  
In order to measure SPC gene expression and telomere length in parallel under the same cell culture 
conditions, cells were seeded and treated and 24 hours later the supernatant was harvested for RNA 
extraction and measuring gene expression, and remaining cells attached to the plate, were fixed to 
enable telomere measurement.  
To establish the number of cells and the optimal coating required to allow measurement of telomere 
length via HTQ-FISH techniques in ATII cells, a 96 well plate was prepared with 3 different coatings, 
and controls without coating, and seeded with 100,000 200,000, 300,000 and 400,000 cells per well.  
96-well plate coatings 
Poly-L-Lysine solution 0.1% from Sigma was diluted 1:1 with Milli-Q water and 100 μl was plated per 
well. 
1.02 mg of Gelatin from porcine skin by Sigma was dissolved in 3.2 ml Milli-Q water, filtered through 
a 0.2 μm filter from Minisart, and 100 μl was plated per well. 
0.31 ml of Matrigel matrix from Corning was mixed with 5.69 ml DMEM on ice, and 100 μl was plated 
per well. 
The plate was incubated with coatings at 37ºC for 2 hours, coatings were then discarded, wells were 
rinsed with DMEM before cells were seeded.  
Plate fixation for HTQ-FISH 
Supernatants were removed after 24 hours of incubation for RNA extraction, as outlined above, and 
cells attached to the plate were gently rinsed with 100 μl PBS and fixed by adding 200 μl of fixation 
solution containing methanol: acidic acid 3:1 to each well, incubating for 5 minutes then discarding the 
fixation solution. This process was repeated 3 times in total leaving the fixation solution for 45 minutes 
the final time and freezing at -80ºC. The plate was sealed and sent to Madrid for measurement of 
telomere length via HTQ-FISH. 
 
SARS-CoV2 infection of ATII cells  
Directly following extraction, ATII cells were seeded 100,000 cells in 100 μl cell culture medium per 
well on a 96 well plate coated with Matrigel as outlined previously. Cells were taken into the Biological 
Containment Laboratory (BSL-3 laboratory) in the IBBTEC and were infected with SARS-CoV-2. 
Researchers accredited to work in NCB3 security laboratories performed these experiments and 
inactivated the virus by hydrogen peroxide before removing the samples from the BSL-3 laboratory. A 
serial dilution of the virus was performed, and cells were infected with the following: 
0 ul: 0 titres de virus (plaque forming unit (PFU)) MOI= 0 
25 ul: 6.1x104 titres of virus PFU. MOI= 1.25  
14 ul: 5x105 titres of virus PFU. MOI= 0.7 
7 ul: 3.2x104 titres of virus PFU. MOI= 0.35 
3.5 ul: 1.7x104 titres of virus PFU. MOI= 0.175 
1.8 ul: 8.8x103 titres of virus PFU. MOI= 0.09 
0.9 ul: 4.5x103 titres of virus PFU. MOI= 0.045 
0.5 ul: 2.5x103 titres of virus PFU. MOI= 0.025  
3 replicas of each concentration were performed as well as 6 replicas of non-infected control wells. 
Following 24 hours of infection, supernatants were removed, 3 replica wells were combined in 
microcentrifuge tubes and RNA extraction and reverse transcriptase were performed as detailed above 
to enable gene expression analysis. The plate was rinsed with PBS and fixed to be sent for HTQ-FISH 
analysis as outlined above. The virus was inactivated by hydrogen peroxide and RNA extraction was 
performed as outlined above. SYBR green qPCR was performed to enable gene expression analysis of 
SPC and S14, and CDC 2019-nCoV real-time RT-PCR diagnostic panel was preformed to detect virally 
produced RNA and confirm SARS-CoV-2 infection of cells.  
 
CDC 2019-nCoV real-time RT-PCR diagnostic panel 
Table 3: Primers and probes used in 2019-nCoV real-time RT-PCR. 
Target gene/Probe Primer description 
Human Ribonuclease P (RP) 
(extraction control) 
Human RNase P Forward Primer/Probe mix 
Nucleoprotein gene (N1) 2019-nCoV_N1 Combined Primer/Probe mix 
Nucleoprotein gene (N2) 2019-nCoV_N2 Combined Primer/Probe mix 
 
Master mixes were mixed for each target gene RP, N1 and N2 containing 5 μl TaqPath 1-step RT-qPCR 
master mix, 1.5 μl of combined primer/probe mix and 8.5 μl nuclease-free water per number of 
reactions. 15 μl of each master mix was dispensed into the appropriate wells and 5 μl of sample was 
added to each well. Negative controls for each target gene contained 5 μl nuclease-free water. Plates 
were run on Applied Biosystems Real-time PCR instrument. StepOne software from Thermo Fisher 
Scientific was used to run the standard curve (absolute quantification) PCR. Stage 1, 2 minutes at 25ºC; 
1 repeat. Stage 2, 15 minutes at 50ºC; 1 repeat. Stage 3, 2 minutes at 95ºC; 1 repeat. Stage 4, 3 seconds 
at 95ºC, 30 seconds at 55ºC; 45 repeats. Thresholds for gene expression were adjusted on the StepOne 
software and data was exported and analysed in Microsoft Excel.  
 
Cell culture conditions to test the effect of plant extracts on SPC expression 
in ATII cells 
Directly following extraction, ATII cells from two different patients were seeded 100,000 cells in 100 
μl cell culture medium per well on 96 well plates coated with Matrigel as outlined previously. 4 total 
metabolite (TM) plant extracts from Marchantia and 4 total metabolite plants extracts from Arabidopsis 
were suspended in the required volume of DMSO to give a final concentration of 0.4 mg/ml when 2 μl 
was added to wells. Plant extracts were provided by the Institute of Biomedical Research of Barcelona 
(IIBB-CSIC) who are collaborating in this project. Plant extracts were suspended in DMSO due to their 
high liposolubility but because DMSO can be toxic to cells, 2 μl of DMSO was added to control 
conditions. Following the addition of plant extracts, TGF-β was added to give either a final 
concentration of 3 ng/ml or 1 ng/ml. Experiments performed in this laboratory by other students showed 
that TGF-β concentrations of 3 ng/ml and 1 ng/ml activated collagen expression in fibroblasts. Control 
conditions contained TGF-β 0 ng/ml, 1 ng/ml, or 3 ng/ml with 2 μl DMSO and no plant extracts. 6 
replicates of each condition were performed. Cells were harvested and pooled from 3 wells for gene 
expression analysis as detailed previously, providing 2 biological replicas of each condition. Cells 
attached to plates were fixed for HTQ-FISH analysis.  
The plant extracts used in this experiment (TM1-TM8) were all total metabolites from mutant expressor 
lines of Marchantia polymorpha and Arabidopsis thaliana and can be seen in Table 4. 
 
Table 4: Plant extracts from Marchantia p and Arabidopsis t. 
Name Mutant Plant species Colour of pellet 
TM1 Mp_Tak1 Marchantia p beige 
TM2 Mp_Tak2 Marchantia p beige 
TM3 Mp_CYP85mut Marchantia p beige/orange 
TM4 Mp_Det2mut Marchantia p beige/orange 
TM5 At_Col-0 mock Arabidopsis t light brown 
TM6 At_Col-0 sorbitol Marchantia p brown 
TM7 At_BRL3ox Arabidopsis t red 
TM8 At_DWARFox Arabidopsis t light brown 
 
Isolation of human fibroblasts from clinical lung samples 
Samples were cut into 1 mm3 explants and placed on 6 well plates with 10 explants per well in a safety 
cabinet. They were allowed to attach for 10 minutes before gently adding 3 ml of the above-mentioned 
cell culture medium being careful not to detach explants. Plates were incubated at 37°C in 5% CO2. The 
medium was replaced every 4 days. After approximately 3 weeks, fibroblasts were visible in the 
microscope. Once 80% confluence was reached, explants were removed, and cells were rinsed with 1 
ml PBS and cell medium was replaced. The first sub-culture was performed by removing culture 
medium, washing with 1 ml PBS, adding 1 ml 1x trypsin-EDTA to each well and incubating at 37°C 
for 3 minutes. To stop trypsinization, 1ml of culture medium supplemented with 10% FBS was added, 
and cells were centrifuged at 400 xg for 5 minutes at room temperature. The supernatant was discarded, 
the pellet resuspended in culture medium and the cells seeded in a 60 × 15 mm tissue culture dish. Once 
3 passes had been performed, cells were frozen in culture medium containing 10% Dimethyl sulfoxide 
(DMSO). Fibroblasts were defrosted by adding 1 ml warm cell culture medium to the vial of frozen 
cells and gently pipetting up and down until the cells were defrosted. Cells were centrifuged for 3 
minutes at 400 xg and resuspended in cell culture medium. 
Results 
Detection of human ATII cells isolated from clinical lung samples 
ATII cells were successfully isolated from the lung samples of 26 patients. Histochemical staining with 
alkaline phosphatase showed the purity of ATII cells varied between patients from 21% to 51%. Figure 
1 shows some examples of the areas of the scanned slides containing 250,000 cells and used to calculate 
the percentage of ATII cells present (pink/purple-coloured cells). It also highlights the variation in terms 
of cells appearance, number of cells per area and contaminants among patients.  
 
 
Figure 1: Examples of selected areas of alkaline phosphatase histochemical staining of human 
ATII cells (in purple) from clinical lung samples. A, B, C, D, E and F are images from patients 4, 
13, 20, 21, 23 and 24 respectively.  
 
The mean values and standard deviation values of the percentage of ATII cells per purification process 
is 36.3±10.8, with n=10. Table 5 shows the percentage of ATII cells calculated in the patient samples 
which were measured. Samples from patients 4 to 21 were cytocentrifuged after cells had been frozen 
and defrosted whereas samples from patients 23 to 27 were cytocentrifuged directly after extraction. 
Frozen and defrosted cells did not show a significantly lower percentage (Student T test) of ATII cells 
(29,8 ± 4,6; N=4) compared to fresh cells (41,6 ± 4,3; N=5) as can be seen in Figure 2. This result 
shows a tendency of obtaining higher percentage of AT II cells in fresh cells, indicating the possibility 
of loss of ATII cells in the freezing and thawing process. A larger number of samples per group should 
be analysed to define if this tendency could become a significant difference in the percentage of ATII 
cells in fresh cells. 
 
 
Figure 2: Mean percentage of Alkaline phosphatase positive cells from cells that were fresh, and 
cells that had been frozen and defrosted, after ATII cell extraction 
 
Table 5 shows the percentage of ATII cells calculated in the patient samples which were measured. 
Samples from patients 4 to 21 were cytocentrifuged after cells had been frozen and defrosted whereas 
samples from patients 23 to 27 were cytocentrifuged directly after extraction.  
 
Table 5: Percentage of Alkaline phosphatase positive cells in ATII cell extractions 


































Mean percentage of Alkaline 
phosphatase positive cells 
 
ATII cell viability over a 24-hour period 
To Establish cell viability over a 24-hour period, cells from patient 5 were defrosted, counted, and 
seeded as outlined above. 6 replicas were performed. Figure 3 shows the percentages of alive and dead 
cells counted at each 12-hour interval. After 12 hours, viability is seen to decreased but after 24 hours 
there is no significant change in viability compared to 0 hours. At 0 hours the mean average percentage 
of alive cells was 59.1%, this decreased to 50.6% after 12 hours and increased again to 59.0% after 24 
hours. Percentage of ATII cells alive at 0 hours and after 24 hours did not show a significant difference 
(Student T test) between 0 hours (59.1 ± 1.9; N=6) compared to 24 hours (59.0 ± 1.8; N=6).  
 
 
Figure 3: The mean average of alive and dead cells from patient 5 over a period of 24 hours. 
Averages were calculated from 6 replica wells and cells were stained with Trypan Blue and 
counted using a haemocytometer. 
 
SPC expression in ATII cells 0h, 24h and 48h after defrosting  
Initial experiments used 50,000 defrosted ATII cells from patient 5. We do not have an alkaline 
phosphatase analysis for patient 5 but using the mean percentage of ATII cells per sample (29,8%) we 
can assume that approximately 15,000 were ATII cells. No gene expression of either the endogenous 
gene S14 or SPC gene was obtained.  
The number of cells seeded was increased and RNA was extracted at 3 time-intervals; immediately after 









Alive Dead Alive Dead Alive Dead











Time after defrosting (hours)
Cell Viability over 24 hours
defrosted and counted. 2 replicates of 120,000 cells each were prepared for RNA extraction immediately 
after being defrosted. According to the mean percentage of ATII cells per sample, approximately 35,000 
of these cells would have been ATII cells. Remaining cells were plated 100,000 cells (30,000 of which 
would have been ATII) per well in 400 μl of cell culture medium on a 24 well plate. 24 hours later, the 
supernatants of 2 replica wells were harvested, and after 48 hours, cells from the remaining 2 wells 
were harvested for RNA extraction. 
The relative SPC gene expression from defrosted cells (120,000 cells) offered quite a high variability 
between replicas but both were higher that 24 and 48 hours. The relative SPC gene expression from 
cells defrosted and plated for 24 hours (100,000 cells) reduced at least 0,5 arbitrary units in the first 24 
hours following defrosting. The relative SPC gene expression from cells defrosted and plated for 48 
hours (100,000 cells) didn´t reduce significantly more compared to 24 hours. The reduced number of 
replicas performed did not allow us to provide statistical differences (n=2 named as “a” and “b” in 
Figure 4) but showed preliminary changes in SPC expression over 48 hours of ATII cell culture. 
Figure 4 shows the change in SPC expression over a 48-hour period in ATII cells. There was also quite 
a high variability in the expression between the 0h replicas.  
 
 
Figure 4: Relative expression of SPC in ATII cells from patient 5 over a 48-hour period. 0h, 24h 
and 48h refer to the number of hours from the time of defrosting cells to the time of extracting 
RNA and a and b refer to biological replicas. Each biological replica has its own technical 
triplicate 
 
Effect of TGF-β in ATII cells on SPC expression 
TGF-β was chosen to imitate the effects of a cytokine storm in cells because of both the high levels of 
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Expression of SPC in ATII cells over a 48-hour 
period
did not detect any reduction in SPC gene expression due to the three different concentrations of TGF-β 
(0 ng/ml, 1 ng/ml, or 3 ng/ml) in ATII cells. 2 replicas (named a and b) were performed for each 
condition (0 ng/ml, 1ng/ml, and 3ng/ml of TGF-β). To obtain these results, 150,000 cells in 100 μl cell 
culture medium from patient 22 were seeded in 6 wells of a 96 well plate immediately following cell 
extraction. TGF-β stock of 60 ng/ml was diluted in phosphate-buffered saline (PBS) and used to treat 
cells giving a final TGF-β concentration of 1ng/ml or 3ng/ml. An equal quantity of PBS was added to 
the TGF-β 0 ng/ml control wells. 
Figure 5 shows how SPC gene expression is not negatively affected when increasing concentrations of 
TGF-β are used to treat the cells compared to the control sample (no TGF-β). In the graph, a and b refer 
to biological replicas. The general trend shows that SPC expression increased with the addition of TGF-
β. However, there are differences of 2-3 arbitrary units between biological replicas, and differences of 
less than 2 arbitrary units in technical replicas in most cases. 
 
 
Figure 5: Effect of TGF-β on SPC gene expression in ATII cells from patient 22. A and b refer to 
biological replicas. Each biological replica has its own technical triplicate. 
 
Conditions that allow measurement of telomere length via HTQ-FISH 
techniques in ATII cells 
Both the number of cells and the optimal coating required to allow measurement of telomere length via 
HTQ-FISH techniques in ATII cells needed to be established. Initially a 96 well plate coated with poly-































































Effect of TGF-β concentration (ng/ml) on SPC 
expression
60,000 cells proved that at the end of the hybridization process with appropriate primers and probes 
including aggressive temperature conditions (80°C) the number of cells was reduced and was 
insufficient for the analysis of the mean telomere length of the sample. However, telomeres could be 
visualised as red spots, from a specific red fluorophore complementary to DNA-telomere sequence, 
within dapi-stained nuclei in the tested wells as can be seen in Figure 6.  
 
 
Figure 6: Representative fluorescent images of telomeres (red) and nuclei (blue) obtained with 
HTQ-FISH technique containing initial 60,000 cells per well. The number of cells remaining on 
the plate was insufficient for determining telomere length.  
 
To establish the number of cells and the optimal coating required to allow measurement of telomere 
length via HTQ-FISH techniques in ATII cells, another 96 well plate was prepared with 3 different 
coatings, and controls without coating, and seeded with 100,000 200,000, 400,000 cells per well from 
patient 23. 100,000 200,000, 400,000 total cells correspond to 50,000, 100,000 and 200,000 AT II cells 
following Alkaline phosphate analysis according to Table 5. 
Wells containing 300,000 total cells (corresponding to 120,000 AT II cells according to Table 5) from 
patient 24 were seeded directly following cell purification. 
We proved that we could obtain SPC gene expression in plates that are subsequently sent to CNIO for 
telomere length measurement (Figure 7). By combining both techniques with the same sample we 
ensure that we have the methodology ready to test whether differences in telomere length correspond 
to variations in SPC expression within the same sample. 
We observed that in the case of 200,000 total cells, changing the coating did not reduced SPC expression 
by more than the difference between control replicas a and b however Matrigel increased SPC 
expression by over 2 arbitrary units. In the case of 400,000 total cells, SPC expression levels were 
similar in control, Gelatin and Matrigel though expression of SPC on poly-l-lysine was reduced by 
almost 2 arbitrary units compared to control cells. In the case of 600,000 cells, gelatine shows similar 
levels of SPC expression to control cells, expression of SPC in cells on poly-l-lysine is very low and on 
Matrigel is increased compared to control cells. In the case of 800,000 cells, expression of SPC is similar 
to that of 600,000 cells with very low expression in cells on poly-l-lysine and Gelatin however 
expression in control cells is slightly higher than cells on Matrigel. Results can be seen in Figure 7.  
To obtain these results, all cells were seeded in 100 μl cell culture medium and incubated at 37ºC. After 
24 hours of incubation, supernatants were carefully removed and transferred to microcentrifuge tubes 
pooling the contents of two duplicate wells, and RNA was extracted as outlined above to enable analysis 
of SPC expression. Cells remaining on the plate were fixed and sent to CNIO for telomere length 
measurement.  
Cells plated on Matrigel consistently demonstrated expression of SPC equal to or higher than those of 
control cells so except in the case of 800,000 cells where expression was just below that of the control 
cells but still higher than that of poly-l-lysine or Gelatin. For this reason, Matrigel was selected for 
future experiments.  
 
 
Figure 7: Relative expression of SPC with a varying number of cells and different plate coatings 
compared to controls without any coating. P23 and P24 refer to patient 23 and 24 and are 
highlighted in blue and orange respectively. Control a and b are biological replicas. Statistical 
differences cannot be obtained because n=2 (a and b). Each biological replica has its own technical 
triplicate. 
 
Figure 8 shows how SPC expression varies according to number of ATII cells pooled for each RNA 
extraction. Regardless of coating used, 200,000 cells were sufficient to have expression of SPC. In all 
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SPC expression in 600,000 cells with 
different coatings - P24
Matrigel control cells gave a higher expression of SPC. In all conditions 600,000 cells from patient 24 
gave the lowest expression of SPC compared to other number of cells from patient 23. 800,000 cells 
showed a reduced expression of SPC under all conditions except control cells where SPC expression in 
800,000 cells was similar to that of 200,000 cells. The Matrigel coating is selected for following assays 
shown in this study because the SPC gene expression values obtained were the highest (from 1-4 
arbitrary units) compared to the other coatings tested (from 0-3 arbitrary units) in all conditions tested. 
Telomere length has not yet been measured in these samples via HTQ-FISH. 
 
 
Figure 8: SPC expression according to number of ATII cells pooled for RNA extraction seeded 
on different coatings. P23 and P24 refer to patient 23 and 24 and are highlighted in blue and 
orange respectively. Control a and b are biological replicas. Each biological replica has its own 
technical triplicate. 
 
CDC 2019-nCoV real-time RT-PCR diagnostic panel 
Directly following extraction, ATII cells from patients 27 and 28 were seeded 100,000 cells in 100 μl 
cell culture medium per well on a 96 well plate coated with Matrigel. According to Table 5, 50,000 
ATII cells of patient 27 were seeded in each well and we do not have alkaline phosphatase analysis for 
patient 28. Cells were infected with SARS-CoV-2 with 0 ul, 25 ul, 14 ul, 7 ul, 3.5 ul, 1.8 ul, 0.9 ul and 
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as well as 6 replicas of non-infected control wells in each patient. Cells from 3 replicas were pooled for 
RNA extraction to increase the number of cells per assay for SPC gene expression assays. Plates were 
fixed for telomere measurement as outlined above and RNA was extracted and retrotranscribed and 
used for both CDC 2019-nCoV real-time RT-PCR diagnostic panel to confirm SARS-CoV-2 infection 
and to measure SPC gene expression. 
The results of CDC 2019-nCoV real-time RT-PCR diagnostic panel are valid when cycle threshold 
(CT) values for RP are below 40, and cells are infected with SARS-CoV-2 when either N1, N2 or both 
have CT values under 40. Table 6 shows all results for patient 27 were valid and all cells infected with 
a viral titre above 0 were successfully infected. Negative controls were not infected. The general trend 
showed that N1 and N2 CT values inversely correlated with viral titre.  
 
Table 6: CDC 2019-nCoV real-time RT-PCR diagnostic panel of ATII cells from patient 27. CT 
is cycle threshold, Std Dev is the standard deviation between triplicates of the PCR. Viral titre 
units (ul). Undetermined results mean values were too low to be detected by the equipment 
Viral titre 
(ul) 
RP Cт Mean RP Std Dev N1 Cт Mean N1 Std Dev N2 Cт Mean N2 Std Dev 
0 (a) 31,47 0,20 Undetermined Undetermined Undetermined Undetermined 
0 (b) 36,81 1,38 Undetermined Undetermined Undetermined Undetermined 
0.5 37,63 0,01 34,26 0,17 37,48 0,31 
0.9 37,64 0,05 36,03 0,65 39,87 Undetermined 
1.8 36,72 0,34 30,59 0,24 33,88 0,16 
3.5 38,03 0,57 31,75 0,29 34,57 0,20 
7 32,68 0,09 25,89 0,06 31,06 0,77 
14 38,21 Undetermined 32,21 0,27 34,55 1,35 
25 30,58 0,08 24,19 0,16 26,55 0,10 
 
SPC expression in SARS-CoV-2 infected ATII cells  
Results from the qPCRs in patient 28 showed that SPC expression was low in controls, higher SPC 
expression was seen in viral titres of 7 ul and 3.5 ul however standard deviation was also high in these 
samples, and no SPC expression was seen under all other conditions. CT numbers were all above 32 
and many wells were undetermined. In Patient 27, SPC expression was seen in both controls, high SPC 
expression was seen in 25 titres of virus, no SPC expression was seen in viral titres of 14 and 7 and 0.9 
and very low expression was seen in viral titres of 3.5 ul, 1.8 ul, and 0.5 ul. There were also many wells 
with an undetermined CT value. The only viral titre to show SPC gene expression in both patients was 




Figure 9: SPC expression in SARS-CoV-2 infected ATII cells of patient 27 and 28. Controls were 
not infected with the virus and a and b refer to biological replicas. Each biological replica has its 
own technical triplicate. 
 
SPC expression in plant extract treated ATII cells  
Directly following extraction, ATII cells from patients 25 and 26 were seeded 100,000 cells in 100 μl 
cell culture medium per well on 96 well plates coated with Matrigel as outlined previously. According 
to Table 5, 100,000 total cells would be 27,000 ATII cells per well for patient 25 and 40,000 ATII cells 
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SPC expression in SARS-CoV2 infected ATII cells 
P28
plants extracts from Arabidopsis were screened (Table 4). Plant extracts were suspended in DMSO to 
give a final concentration of 0.4 mg/ml when 2 μl was added to wells. 2 μl of DMSO was added to 
control conditions. Following the addition of plant extracts, TGF-β was added to give either a final 
concentration of 3 ng/ml or 1 ng/ml. Control conditions contained TGF-β 0 ng/ml, 1 ng/ml, or 3 ng/ml 
with 2 μl DMSO and no plant extracts. 6 replicates of each condition were performed. Cells were 
harvested by pooling 3 wells for gene expression analysis as detailed previously, providing 2 biological 
replicates of each condition. Cells attached to plates were fixed for HTQ-FISH analysis. 
Figure 10 Shows SPC gene expression in ATII cells in the presence of plant extracts M1-M8 of two 
biological replicas of patient 25 (Figure 10 A and Figure 10 B) and one replica in patient 26 (Figure 
10 C) all from plates where 3 ng/ml TGF-β was added to all wells except controls. Results from other 
conditions (patient 26 replica a, and plates with TGF-β 1ng/ml) are still pending. Figure 10 A shows 
that expression of SPC does not appear to be altered significantly by the addition of plant extracts except 
in the cases of plant extract M3 where cycle threshold was undetermined in both S14 and SPC, and in 
the case of M4 where expression of SPC was higher compared to control cells. Figure 10 B shows SPC 
expression in TGF-β 3ng/ml is higher than the control and wells containing plant extracts. In biological 
replicas b, SPC expression with TM3 is observed and SPC expression in the presence of TM4 is reduced 
contrary to replicas a. Figure 10 C shows no SPC expression in presence of TM2 and highest SPC 
expression in the presence of TM7, unlike Figure 10 B where SPC expression in the presence of TM7 
was the lowest of all conditions. Overall, SPC expression between all conditions does not vary more 
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Figure 10: A) SPC gene expression in ATII cells from patient 25 replicas (a), treated with plant 
extracts 1-8 (M1-M8). B) SPC gene expression in biological replicas (b) of patient 25. C) SPC gene 
expression of ATII cells from patient 26 replica (b). All wells were treated with 3 ng/ml TGF-β 
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SPC expression with TGF-β 3ng/ml and TM1-TM8 Patient 26 bC
Cell culture of human fibroblasts from clinical lung samples 
Human fibroblasts were successfully isolated from 3 patient´s lung samples. It took approximately 2 
weeks for fibroblasts to become visible in the microscope. An image of the cells can be seen in Figure 








In this study, we analysed the purity of ATII cells when extracted from human lungs, the maintenance 
of ATII homeostasis under different cell culture conditions, TGF-β treatments and SARS-CoV-2 
infection and looked for the preservation of ATII cell health by the addition of plant extracts. Moreover, 
ATII cells were prepared under the conditions required to allow measurement of their telomeres by 
HTQ-FISH techniques in collaboration with the CNIO. 
In addition, successful purification and cell culture of human lung fibroblasts were achieved to enable 
further assays to test the generation and prevention of fibrosis. 
 
Isolation and histochemical staining of human ATII cells from clinical lung 
samples 
Histochemical staining of ATII cells highlights the variability of patients and the low percentage of 
ATII cells. Improvements should be made in some key purification steps, such as reducing the size of 
the cut lung pieces before filtering, or longer incubations to remove adherent cells.  
The percentage of alkaline phosphatase positive ATII cells (especially from frozen cells) was very low, 
this could explain lack of, or low gene expression in some initial experiments. Some samples had a 
higher total concentration of cells on the microscope slide, potentially limiting the penetration of 
alkaline phosphatase therefore leading to an under-estimation of the actual percentage of ATII positive 
cells. Considerable variation was also seen between patients in the amount of blood cell contamination 
and other lung contaminants. Therefore, it is quite possible that, depending on the type of pathology 
that patients present before undergoing surgery, or the medications being taken by patients, that the 
number of ATII cells present per lung area may be different. It is important to note that most patients 
smoke, which was visible in the samples as black areas.  
 
ATII cell viability over a 24-hour period 
Human ATII cells can maintain their phenotype in culture for at least 24 hours. This observation is very 
valuable because treatments in the presence of TGF-β, SARS-CoV-2 and/or plant extracts are 
performed during this time period.  
The decrease in viability percentage observed after 12 hours is likely to be because at that time point, 
the sample was taken from the supernatant for counting, and not from the total (attached and suspension 
ATII cells), therefore alive cells which have attached to the plate were not considered, whereas dead 
cells would not attach meaning that a higher percentage of dead cells was observed in the supernatant. 
We conclude that these measurements should be done from the total of cells present in the assay. The 
results are also limited to one patient so may not represent cell viability in other patients. The method 
is limited to viability of nucleated cells and does not indicate if cells have differentiated. The method 
of counting cells also contains a relatively high degree of inaccuracy especially in primary cultures of 
cells where tissue residues remain and can easily be confounded with dead cells when stained with 
trypan blue. Removing cell debris and increasing the number of patients measured would improve the 
method.  
 
Change in SPC expression in ATII cells 0h, 24h and 48h after defrosting  
The results of SPC gene expression over time in culture show a remarkable drop in SPC expression in 
the first 24 hours of culture. Possible explanations could be that ATII cells could be dying or unhealthy, 
and therefore producing less SPC, or differentiating to non-SPC producing ATI cells. Total number of 
cells per extraction was higher in the 0h extractions and although defrosted cells were from the same 
patient, cells were taken from a different vial than those which had their RNA extracted after 24 and 48 
hours so these factors could account for some of the difference observed. These results did not seem to 
support the results from the cell viability experiment using trypan blue however this could be due to 
patient variability or due to a certain percentage of cells changing phenotype, thus no longer producing 
SPC.  
Cycle threshold (Ct) values were in the range of 23 and 29 for SPC expression at 0h however at 24- and 
48-hours Ct values were in the range of 32 to 36 which is too high for control conditions to enable 
reliable comparison between control and treated conditions. This experiment was only performed in 
one patient, so cell viability is likely to vary considerably between patients. To address this problem, 
we increased the number of cells being used, reduced maximum incubation time from 48 hours to 24 
hours and tested different plate coatings to reduce the range of Ct numbers by improving cell culture 
conditions to maintain ATII cell homeostasis. To improve this method cells would need to be defrosted 
at the same moment and divided into replicas of equal numbers for 0 hour, 24 hours, and 48 hours. 
More than one patient should be used, the number of cells in each condition could be increased to reduce 
Ct values and the number of replicas of each condition should be at least 3 in each condition in order to 
optimise the working conditions to obtain more reproducibility. 
 
Effect of different culture dish coatings and cell number of SPC expression 
in ATII cells and conditions required for measurement of telomere length 
via HTQ-FISH techniques 
ATII cells grow in suspension so either an insufficient number of cells were adhering to the preliminary 
culture plate sent for HTQ-FISH analysis or too many cells were becoming detached and lost during 
the stringent process. It was essential to find a coating that would allow a 24-hour treatment without 
promoting apoptosis or differentiation of cells and promote sufficient adhesion to the plate. Different 
cell culture plate coatings were tested for variability of SPC expression. Preliminary results showed 
differences between the coating tested with Matrigel being the more stable coating maintaining SPC 
expression. This is supported by a study that used gene expression profile analysis to compare freshly 
isolated human ATII cells growing on a Matrigel coating with those grown on a type I collagen coating 
over a 3 day period and found that Matrigel preserved ATII cell phenotype while collagen promoted 
differentiation (30). It is possible that there is a difference between cells remaining in suspension and 
those attached to the plate so the experiment could be repeated by extracting RNA from the supernatant 
and separately extracting RNA from the cells that remain attached to the plate to measure SPC 
expression enabling comparison. There is a clear decrease in SPC gene expression above 400,00 cells. 
In the case of 600,000 cells this could be explained by patient variability but with 800,000 cells of the 
same patient, SPC gene expression is also low. This could be because seeding such a high concentration 
of cells in 100 μl of cell culture medium could provide insufficient nutrients to cells and reduce their 
viability. A total of 200,000 cells per RNA extraction was sufficient to have SPC gene expression in 
two different patients and in on all coatings assayed. Results for the HTQ-FISH analysis are essential 
to determine the most suitable coating and number of cells required for future experiments.  
 
Effect of TGF-β in ATII cells on SPC expression 
This experiment was limited to only 2 replicas for each condition and 2 different concentrations of TGF-
β because the number of cells extracted from patient 22 was low and did not allow for more. The results 
did show a tendency that SPC gene expression increased with an increasing concentration of TGF-β but 
to test whether or not this was actually the case or whether it was just due to the variability between 
replicas it would be necessary to repeat the experiment with more biological replicas. Another limitation 
of this experiment is that TGF-β is used to imitate COVID-19 infection in ATII cells but TGF-β alone 
is not representative of the cytokine storm.  
 
CDC 2019-nCoV real-time RT-PCR diagnostic panel 
This experiment demonstrated it was possible to infect ATII cells and for the virus to transcribe viral 
mRNA within cultured ATII cells. The results also showed that all viral titres assayed were sufficient 
to infect cells and be detected after a 24-hour incubation in cells from patient 27. The 2019-nCoV qPCR 
of patient 28 showed very high background noise confounding results so the experiment will need to be 
repeated. 
 
SPC expression in SARS-CoV-2 infected ATII cells  
Preliminary results show 3.5 ul titre of virus was the only concentration whereby cells were confirmed 
to be infected and SPC gene expression was obtained in both patients. In all cases, controls showed 
expression of SPC indicating that lack of expression or increase in SPC expression could be due to viral 
infection. Reproducibility of results between patients was very poor which could be due to patient 
variability or the baseline variability observed between biological replicas, however, to confirm this, 
the experiment would need to be repeated. It is necessary to infect cells with a concentration of virus 
that does not kill all cells within a 24-hour period so that SPC expression can be measured and compared 
between treatment groups.  
During the process of inactivating the virus with hydrogen peroxide to take samples out of the BSL-3 
laboratory, samples were left incubating in NYZol for the duration of this cycle (90 minutes) and due 
to a technical error, this cycle had to be repeated, therefore increasing the usual incubation time of 5 
minutes in NYZol to 3 hours. This could have had led to degradation of the RNA in samples and could 
be why no SPC expression was observed in some conditions. Due to the poor reproducibility of results 
between patients this experiment should be repeated before selecting a viral titre for future experiments.  
 
SPC expression in plant extract treated ATII cells  
Because of the low overall range of relative SPC gene expression, differences in expression can be 
attributed to the usual degree of variation seen in the expression of SPC between biological replicas 
which in previous experiments was up to 2.5 arbitrary units, and between cells from different patients 
and is unlikely to be due to properties of the plant extracts added as these differences were not 
reproduced. The lack of expression seen in some replicas was also not reproduced in other replicas, or 
in cells from another patient, so is likely to be due to a technical error at some point during the 
processing of the sample and unlikely to be due to toxicity of the plant extract. The results currently 
indicate that none of the plant extracts at a concentration of 0.4 ng/ml, or TGF-β at a concentration of 
3 ng/ml, significantly alter SPC gene expression in ATII cells over a 24-hour period. The results also 
demonstrate that none of the plant extracts are highly toxic to ATII cells over a 24-hour treatment 
period. To further confirm these results more technical replicas of qPCRs should be performed to allow 
for statistical analysis. The results do not however indicate if either the plant extracts or TGF-β can 
cause a change in SPC gene expression in ATII cells in different concentrations. The assays would need 
to be repeated varying the concentrations of TGF-β and plant extracts to assess which concentrations 
do or do not have an effect. TGF-β has been used in these experiments to recapitulate COVID-19 disease 
but many other cytokines and chemokines are involved in COVID-19 disease, therefore using only 
TGF-β is not very representative of a SARS-CoV-2 infection and these experiments will need to be 
repeated using the virus instead of TGF-β. These experiments have, however, allowed us to optimise 
conditions, such as using fresh ATII cells instead of frozen cells, using a higher number of cells and 
using a plate coating in order to optimise cell viability and enable measurement of SPC gene expression.  
 
Isolation of human fibroblasts from clinical lung samples 
Initial experiments have been conducted by another member of the same laboratory group to measure 
expression of collagens 1 and 3, and fibronectin and how this expression changes in the presence of 
TGF-β and the plant extracts. Once experimental conditions have been established it will be possible to 
incubate fibroblasts and ATII cells together in the same well to see if infection and treatment of ATII 
cells produces a change in expression of collagens 1 and 3, and fibronectin.  
 
Further research 
This study has provided the preliminary steps for the conditions required to analyse changes in SPC 
gene expression in ATII cells under different treatment conditions. The conditions required to allow 
measuring both the change in SPC gene expression and measurement of telomere length by HTQ-FISH 
techniques within the same biological replica, have been assayed and definitive results from the CNIO 
are still pending. Further research will include treating ATII cells with plant extracts, subsequently 
infecting them with SARS-CoV-2 and measuring if there is any change in SPC gene expression. The 
supernatant of these ATII cells growing in suspension can be applied to a monolayer of fibroblasts so 
that, not only can the SPC gene expression be measured, but any change in fibrotic response can also 
be indicated by measuring the relative expression of collagens 1 and 3, and fibronectin in fibroblasts, 
and whether or not there are plant extracts which are able to protect against a fibrotic response.  
Conclusions  
1: ATII cells were successfully extracted and purified from clinical lung samples and their purity was 
confirmed enzymatically.  
 
2: ATII cell viability over a 24-hour period was shown not to decrease significantly and the total number 
of cells required to yield sufficient quantities of RNA to allow for retro-transcription and detection of 
SPC was determined to be 200,000 cells, however, this varied between patients.  
 
3: The addition of 1ng/ml and 3 ng/ml TGF-β did not produce a significant difference in the expression 
of SPC in ATII cells compared to control conditions with 0 ng/ml TGF-β. 
 
4: Preliminary results indicate that seeding 100,000 cells per well onto Matrigel and pooling 2 wells for 
RNA extraction were the optimal conditions to allow measurement of SPC expression, while the 
measurement of telomere length via HTQ-FISH techniques of cells remaining attached to the plates are 
still pending results from the CNIO. 
 
5: Total metabolites of 4 plant extracts from Marchantia and total metabolites of 4 plant extracts from 
Arabidopsis showed no considerable change on the relative SPC expression in ATII cells compared to 
control conditions. 
 
6: Preliminary results indicate 3.5 ul titre of virus in 100,000 cells seeded in 100 ul cell culture medium 
to be the optimal conditions for SARS-CoV-2 infection of ATII cells. 
 
7: Primary human fibroblasts were successfully isolated and cultivated from clinical lung samples 
obtained from biopsies for future experiments. 
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